{"id":391714,"date":"2014-03-20T00:00:00","date_gmt":"2014-03-20T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dbascg0514-biopharma-multiple-sclerosis-chronic-progressive-decision-base-us-2014\/"},"modified":"2026-03-31T09:05:41","modified_gmt":"2026-03-31T09:05:41","slug":"dbascg0514-biopharma-multiple-sclerosis-chronic-progressive-decision-base-us-2014","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dbascg0514-biopharma-multiple-sclerosis-chronic-progressive-decision-base-us-2014\/","title":{"rendered":"Multiple Sclerosis (Chronic-Progressive) | Decision Base | US | 2014"},"content":{"rendered":"<p><em>Amid Substantial Unmet Need, What Magnitude of Efficacy and Safety Do Neurologists and Payers Expect of a First-To-Market Therapy for Primary-Progressive Multiple Sclerosis?<\/em><\/p>\n<p>Despite contributing a relatively modest fraction to the overall multiple sclerosis (MS) population, the chronic progressive MS (CP-MS) subpopulation (comprising secondary-progressive MS [SP-MS] and primary-progressive MS [PP-MS]) presents considerable opportunity for the development of novel therapeutics. PP-MS patients, in particular, are significantly underserved at present due to the complete lack of proven effective disease-modifying therapies as a result of the repeated failure of clinical trials in this patient subtype to date. However, a growing number of current and emerging therapies are being evaluated specifically in the PP-MS subpopulation. Surveyed neurologists and managed care organization pharmacy directors (MCO PDs) both identify a greater effect on physical disability as one of the top unmet needs in PP-MS. Indeed, in terms of impact on prescribing decisions, improvements in efficacy will likely outweigh comparable improvements in other areas such as safety and delivery.<\/p>\n","protected":false},"template":"","class_list":["post-391714","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-multiple-sclerosis","biopharma-geography-us","biopharma-date-574"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391714","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391714\/revisions"}],"predecessor-version":[{"id":394837,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391714\/revisions\/394837"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391714"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}